Status:
COMPLETED
Intranasal Oxytocin and Enhancement of Team Cohesion
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
United States Department of Defense
San Francisco Veterans Affairs Medical Center
Conditions:
Unit Cohesion
Eligibility:
All Genders
18-28 years
Phase:
PHASE1
Brief Summary
This study attempts to identify the psychological, behavioral, physiological, and hormonal predictors and mechanisms of an individual's ability to develop cohesion in a group working together as a tea...
Detailed Description
The investigators will study up to one thousand subjects who will be randomized into same-gendered teams of three or volunteer as acquainted groups of three . Teams will be randomized to receive oxyto...
Eligibility Criteria
Inclusion
- Age 18-28
- Speak English
- Ability to use a nasal spray
Exclusion
- Positive urine pregnancy test
- History of psychiatric or neurologic disorder
- Use of illicit drugs in the past month
- History of moderate-severe alcohol use disorder as defined by DSM-V criteria
- Sensitivity to preservatives (in particular E 216, E 218 and chlorobutanol hemihydrate)
- Nasal obstruction, discharge, or bleeding
- Habitually drinks large volumes of water
- Taking testosterone, estrogen/progesterone supplement, or serotonin-1a receptor agonists/antagonists
- Currently meets Diagnostic and Statistical Manual-5 (DSM-V) criteria for severe major depressive disorder with suicidal thoughts or actions
Key Trial Info
Start Date :
October 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 31 2019
Estimated Enrollment :
486 Patients enrolled
Trial Details
Trial ID
NCT02302430
Start Date
October 1 2015
End Date
May 31 2019
Last Update
August 5 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
San Francisco VA Medical Center
San Francisco, California, United States, 94121